Inhalation Sciences (ISAB) has named TFS Trial Form Support International Founder Daniel Spasic as Chairman of the Board. Spasic serves on the boards of several other companies, including connected spirometer maker NuvoAir.
In May 2019, Inhalation Sciences announced that it intended to validate its PreciseInhale dosing system, which produces aerosols at a specified dose and particle size distribution, for clinical use. At the time, ISAB sold off shares in its spinoff Ziccum to finance the validation study, and the company recently sold off its remaining shares. ISAB also makes the DissolvIt system for in vitro simulation of absorption and dissolution in the lung.
Spasic commented, “I’d spent a lot of time in respiratory clinical research before, but not so much on the preclinical or in vitro, in vivo side. Plus, I could see that ISAB had a long history, but with modest sales and revenues. So, I felt the need to talk to advisers in my respiratory network and find out more about where in the drug development continuum PreciseInhale and DissolvIt would fit and add most value to research. I talked to respiratory physicians, Scientific Advisory Board members and so on. One of the advisors had recently completed a clinical Phase 2 study on a new respiratory treatment. He provided some very valuable feedback: ‘if we’d known about this instrument two years ago, we wouldn’t have had an inclusive Phase 2 clinical trial that absorbed so much development costs and time.’ For me that really confirmed the Inhalation Sciences business case. After receiving such feedback from a senior advisor, I simply thought— ‘OK, this company really has a technology that can change respiratory drug research into something much better and more efficient.’”
Spasic suggests that the COVID-19 pandemic will increase the amount of respiratory research, saying “Inhalation science has been expanding for a long time, but when you look at what drug and treatments are currently available, I’d say they have plateaued a little. Right now, people are looking for next-generation inhalation solutions, whether devices or drugs, that can further improve the health of patients. It’s extremely rewarding to be part of that journey.”
Read the Inhalation Sciences press release.
